Study of Loestrin 24(24 Days of "Real" Pills) Fe Versus Loestrin 1/20 (21 "Real" Pills)
Completed
Warner Chilcott
N/A
2007-06-01
The purpose of this research study is to assess hormone withdrawal symptoms in women while
taking an oral contraceptive in the novel 24/4 (24 days of "real" pills) manner in comparison
to taking pills in the standard 21/7 (21 "real" pills) manner.
It is hypothesized that the 24/4 method will reduce common hormone withdrawal symptoms
compared to the standard 21/7 regimen.
It is further hypothesized that women using the 24/4 regimen will report greater satisfaction
scores.
Study of Loestrin 24(24 Days of "Real" Pills) Fe Versus Loestrin 1/20 (21 "Real" Pills)
Completed
Scott and White Hospital & Clinic
N/A
2007-06-01
The purpose of this research study is to assess hormone withdrawal symptoms in women while
taking an oral contraceptive in the novel 24/4 (24 days of "real" pills) manner in comparison
to taking pills in the standard 21/7 (21 "real" pills) manner.
It is hypothesized that the 24/4 method will reduce common hormone withdrawal symptoms
compared to the standard 21/7 regimen.
It is further hypothesized that women using the 24/4 regimen will report greater satisfaction
scores.
Optimizing Ovulation Induction in the Poor Responder
Withdrawn
Emory University
N/A
2010-10-01
The purpose of this randomized controlled trial is to compare the efficacy and effect of
luteal estradiol and combined oral contraceptive pills (COPC) on follicle recruitment and
synchrony in a poor responder population. The randomized groups consist of: 1. patients
receiving luteal estradiol prior to ovulation induction; and 2. patients receiving COCPs for
1 month prior to ovulation induction. Follicle characteristics and serum biomarkers will be
followed and compared in each group. Coefficient of variation will be used to evaluate
follicle size discrepancy. Chi square analysis will be used to compare categorical variables
between treatment groups. Both estradiol and COPCs are used clinically in assisted
reproduction, so this study affords no additional risks to the participants.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
